Lexeo reports positive phase 1/2 data for LX2020

by | 18th Nov 2026 | News

Regulatory progress supports accelerated approval pathway

Lexeo Therapeutics has reported positive interim results from its ongoing phase 1/2 HEROIC-PKP2 clinical trial evaluating LX2020 in patients with PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM), alongside a regulatory update that may support an accelerated approval pathway.

The company said LX2020 was generally well tolerated across 10 participants treated in the study, with no clinically significant complement activation observed and no study discontinuations reported.

Data from the high-dose cohorts showed an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) and a 44% mean reduction in premature ventricular contractions (PVCs) at the latest assessment compared with baseline.

Lexeo said six of seven participants in the high-dose groups demonstrated improvement in NSVT burden, while five of seven showed reductions in PVC burden. Five participants also reported symptom improvement relative to baseline.

The company reported preliminary evidence of stabilisation or improvement in cardiac function in most participants receiving the higher dose, based on cardiac MRI assessments.

In discussions with the US Food and Drug Administration (FDA), Lexeo said the agency was open to the use of guideline-defined NSVT as a primary surrogate endpoint in a pivotal study designed to support accelerated approval.

R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, said: “These data further strengthen our confidence in LX2020 and its potential to address the underlying biology of PKP2-ACM. The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM.”

He added: “Our regulatory discussions also provide important clarity on the path forward, including the FDA’s openness to the use of NSVT as a primary endpoint in a planned pivotal study given the well-established association between NSVT and sustained, life-threatening arrhythmic risk.”

Walker Frahm, Chief Executive Officer of the Foundation for Inherited Arrhythmias, explained: “Our community has waited a long time for treatments that might address the underlying cause of this disease. Early results like these give ACM families reason to hope for better, more targeted care.”

Lexeo expects to finalise the design of its pivotal study during the first half of 2027 and initiate the trial in the second half of the year.

Tags


Related posts